Article

The architecture of clinical research

Author and Disclosure Information

 

References

“Compliance bias” is a subset of performance bias which occurs when 2 conditions are satisfied: (1) the main maneuver is not administered adequately, and (2) the investigator is unaware of that nonreceipt so that this cannot be accounted for in interpreting the study results. For example, if a drug has efficacy but if no one in the treatment arm of the trial takes the drug, the absence of a difference in outcomes between the compared groups will be ascribed to nonefficacy, whereas “compliance bias” (ie, no one actually took the drug) could actually be the cause. Ideally, randomized studies should be evaluated on an “intention to treat” basis irrespective of compliance, but there is an analytic approach called “per protocol” analysis in which you can analyze the results according to whether the patient actually used the intervention in an effective way. “Per protocol” analysis is a secondary analysis of the primary results but it can nonetheless help determine whether the negative result is likely related to noncompliance or not.

A third type of internal bias, “detection bias,” is fairly straightforward. Detection bias is related to how avidly and how comparably the outcomes are measured between the 2 compared groups. Let’s say that you are conducting a trial of a new antibiotic and the primary outcome is colony counts on petri dishes of plated collected specimens. If the technicians who read the petri dish counts are unblinded, they may look at the colony counts with a biased eye, seeing fewer colonies on plates collected from patients receiving the antibiotic.

Overall, detection bias occurs when outcomes are ascertained or detected unequally between the compared groups, and detection bias can involve any of the following: is there comparable surveillance of the 2 groups for analysis of the outcome measure? Are the diagnostic tests comparably performed in both groups and is the interpretation comparably unbiased with equipoise? Investigators who know which patients are receiving an active drug and those who are not could experience subliminal bias that renders them more likely to find that the drug under study is efficacious.

Depending on the principal study maneuver, ensuring blinding can be challenging. To demonstrate this point, let’s consider the example of conducting a randomized control trial of Vicks VapoRub. Vicks VapoRub is an old product that smells like wintergreen and that mothers used to rub on the chests of their infants in the hope of speeding recovery from colds and bronchitis episodes. It was felt that the distinctive smell of the product was materially related to wintergreen, which gives rise to the odor. So, imagine a randomized trial of Vicks VaporRub. A trial is designed in which sick children receive Vicks VapoRub on their chest and others receive a placebo rub that lacks the distinctive wintergreen odor. But, the odor itself is felt to be related to how Vicks VapoRub actually works. Thus, it is the odor itself that creates the blinding challenge here.

The primary outcomes in this study are the duration of the child’s cold symptoms, as ascertained by pediatricians actually examining the children. So, pediatricians would come and listen to the infants’ chests: “Yeah, this chest is clear, but this other infant is still full of rhonchi,” and they would ascertain the outcome measure in this way. So, my blinding question to you is: how do you blind a trial of Vicks VapoRub given the conditions described? Namely, you put the VapoRub on the chest, it smells and the smell is the intervention—how do you blind such a trial?

The clever answer is that you should put Vicks VapoRub on the upper lips of all the examiners, so what they smell is Vicks VapoRub independent of whether the child they are examining also has the Vicks VapoRub or placebo on their chest. In this way, single blinding of the examiners is preserved and detection bias is averted. It is important to point out that double blinding could also be achieved by placing Vicks VapoRub on the child’s upper lip, but there is little reason to suspect that the infants being studied have a bias related to whether they smell the Vicks VapoRub.

The fourth potential source of internal bias is called “transfer bias.” Transfer bias is the selective loss to follow-up of patients from 1 of the 2 compared groups in the trial for a systematic reason. By systematic, I mean that that the drop-out is associated with the development of the outcome event or some impact of the intervention regarding the likelihood to develop the outcome event. As an example, if all patients respond favorably to a drug and everybody fails to follow up because they feel too good to come back, then that would bias the study towards nonefficacy even in the face of an efficacious intervention.

Finally, let’s consider a source of bias that can affect the “external validity,” or the generalizability of the study results to populations other than that included in the study itself. Dr. Feinstein calls this 5th type of bias “assembly bias” (Table 1).1 Assembly bias occurs when the results of the study cannot be reliably applied to populations outside the study itself.

For example, if I screen patients during a study of digoxin for heart rate control in atrial fibrillation, I could establish whether the subject was compliant or not by checking his/her serum digoxin levels. Serum levels of 0 indicate that the patient has not taken the digoxin. If I include a run-in period for the trial—an interval before the actual study when I am assessing potential subjects’ eligibility to participate—and check serum digoxin levels to include only patients who are shown to be taking the drug, then I am screening for study inclusion on compliance. In this way, I will have assembled a population that is highly compliant so that I can truly assess whether digoxin has efficacy in controlling the heart rate in patients with atrial fibrillation. At the same time, this study population is not highly representative of the population of patients with atrial fibrillation at large, because we know that rates of drug noncompliances may be as high as 30% to 40%. So, culling a population with run-in periods on demonstrated compliance criteria may be very important to assess efficacy (ie, whether the drug works), but this design will trade off on the effectiveness of the drug (ie, which asks the question “does the drug work in actual practice?”). This is because, in the yin-yang between assessing efficacy and assessing effectiveness, the focus on assessing efficacy naturally undermines the ability to assess whether the drug works in real-world conditions.

As another example of potential assembly bias, let’s say you are studying an antihypertensive drug at a Veterans Administration (VA) hospital, where most veterans are men. But you are treating women in your practice and wonder whether the drug, which works in a predominately male population, will work in your female patients. So, there could be assembly bias in applying the results of a VA study to a non-VA predominantly female population.

Having now described the design of clinical trials and the major sources of bias, let’s apply this thinking to the earliest clinical trial. James Lind, a British Naval officer, was credited with conducting the first clinical trial of citrus fruits for scurvy while sailing on the ship Salisbury in 1747.2 The question that Lind addressed was “does citrus fruit treat and prevent scurvy?” In describing this trial, Lind stated “I took 12 patients with scurvy, these patients were as similar as I could have them, had one diet common to all.” As you read this through your new Feinsteinian bias lens, Lind is addressing 2 potential sources of bias, namely, susceptibility bias and performance bias. In trying to make the “cases as similar as I could have them,” he is trying to avoid susceptibility bias and in “providing one diet common to all,” he is trying to avoid performance bias.

In terms of the intervention in this trial, these 12 patients were allocated in pairs to several interventions: a quart of cider a day, 25 drops of elixir of vitriol 3 times a day on an empty stomach, 2 spoonsful of vinegar 3 times a day on an empty stomach, ½ pint a day of sea water, 2 oranges and 1 lemon given every day, and a “bigness of nutmeg” 3 times per day. In describing the outcome of the trial, Lind states “the consequence was that the most sudden and visible good effects were perceived from the use of oranges and lemons; one of those who had taken them, being at the end of 6 days fit for duty. The spots were not indeed at that time quite off his body, nor his gums sound, but without any other medicine then a gargarism of elixir vitriol, he became quite healthy before we came into Plymouth which was on the 16th of June. The other was the best recovered of any in his condition; and being now deemed pretty well, was appointed nurse to the rest of the sick.”

Next Article:

Basics of study design: Practical considerations

Related Articles